In a single institutional study (M.D. Anderson), 60 older patients with chronic lymphocytic leukemia were treated with lenalidomide. Thirty-five of the 60 patients had a response lasting > 36 months, and compared with those who did not have such a durable response, those who did had lower pretreatment β-2 microglobulin levels and were more likely to have favorable cytogenetics. Lenalidomide treatment was associated with improvement in circulating immunoglobulin levels and T-lymphocyte numbers.SOURCE:
Strati P, et al. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood 2013;122:734-737.